Letrozole for Ovulation Induction: Dosing and Protocols

Standard Dosing Protocol

The standard dose of letrozole for ovulation induction is 2.5 mg daily for 5 days, starting on cycle days 3-7, with dose escalation up to 7.5 mg daily in subsequent cycles for inadequate response 1
The American College of Obstetricians and Gynecologists recommends continuing letrozole for 3-6 cycles before considering alternative interventions 1, 2

If pregnancy is not achieved after 3-6 cycles, the American Society for Reproductive Medicine suggests adding intrauterine insemination (IUI) to letrozole treatment 1, 2
The European Society of Human Reproduction and Embryology recommends considering combination therapy with other fertility treatments for inadequate responders 2
The American College of Obstetricians and Gynecologists advises referring for IVF if letrozole treatment (with or without IUI) is unsuccessful after an appropriate trial 1, 2

The American College of Obstetricians and Gynecologists mandates ultrasound monitoring during each treatment cycle to ensure appropriate follicular development and reduce multiple pregnancy risk 1, 2
The American Society for Reproductive Medicine recommends monitoring follicle size and number during each cycle 1
The European Society of Human Reproduction and Embryology suggests monitoring endometrial thickness, as letrozole maintains adequate endometrial development even at high doses 1

Letrozole offers several benefits over clomiphene citrate, including maintaining estrogen levels near physiologic ranges, reducing OHSS risk 1
The American College of Obstetricians and Gynecologists notes that letrozole may be beneficial for patients with antiphospholipid antibodies or thrombophilia due to lower peak estrogen levels 1
The European Society of Human Reproduction and Embryology recommends using letrozole during ovarian stimulation without reducing mature oocyte yield or fertilization capacity 1

The American College of Obstetricians and Gynecologists warns against skipping ultrasound monitoring, as it is essential for preventing multiple pregnancies and confirming appropriate follicular response 1
The American Society for Reproductive Medicine advises against using aromatase inhibitors alone in premenopausal women for breast cancer treatment, as they are ineffective without ovarian suppression and are contraindicated in this population 1

The European Association of Urology notes that letrozole and other aromatase inhibitors are used off-label in male infertility to improve hormonal and semen parameters with a safe tolerability profile, though prospective RCTs are needed to better define efficacy 3, 4, 5

Ovulation generally occurs within 7-9 days after the last letrozole pill, meaning if you started on day 3 and finished on day 7, ovulation would likely occur around cycle days 14-16, according to the MMWR Recommendations and Reports 6

During an average 28-day cycle, ovulation generally occurs during days 9-20, as reported by the MMWR Recommendations and Reports 6
Random start stimulation is possible with letrozole, meaning treatment can begin at any point in the menstrual cycle, though this affects the calculation of when ovulation will occur, as noted in the Annals of Oncology 7

Letrozole inhibits the aromatase enzyme, producing a temporary reduction in estrogen synthesis during the early follicular phase; this reduction stimulates an increase in follicle‑stimulating hormone (FSH) secretion and promotes follicular development comparable to a natural cycle. 8

Certain ingested substances—such as poppy seeds, pseudoephedrine, and dextromethorphan—may generate false‑positive results in urine immunoassays, but they do not interfere with luteinizing hormone (LH) ovulation predictor kits used during letrozole cycles. 9